Orchid Gets USFDA Nod for Cephalexin

by Medindia Content Team on  July 12, 2006 at 8:36 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

Orchid Gets USFDA Nod for Cephalexin
Orchid Chemicals & Pharmaceuticals Ltd today said it has received approval from the USFDA for its ANDA (Abbreviated New Drug Application) of Cephalexin oral suspension.

Cephalexin, an off-patent molecule, forms part of Orchid Chemicals' distribution alliance with US generic pharma major Par Pharmaceuticals Inc, it informed the Bombay Stock Exchange.

Orchid added that its Cephalexin capsules are already marketed in the US through partnership with Par Pharmaceuticals and following this approval, the number of dosage forms, oral solids and injections distributed by it in the US now stands at 12.

The company's shares were trading at Rs 185.30, up 1.12 per cent at the BSE.

Source:PTI News

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive